Diagnosis, Staging and Treatment of Patients with Rectal Cancer

Objectives

Provide national, evidence-based clinical guidance for health professionals on the diagnosis, staging and treatment of adults aged 18 years or over with suspected or newly diagnosed early or locally advanced rectal cancer, improving care quality, consistency, safety, effectiveness and cost-effectiveness across Irish services.[1][2][3][4][5]The guideline integrates research evidence, clinical expertise and patient values, focuses on priority areas of uncertainty, practice variation, emerging evidence and likely impact on patients and services, and supports clinical governance in primary and secondary care.[3][4]

• Improve accurate diagnosis and staging through contrast-enhanced computed tomography of the thorax, abdomen and pelvis, magnetic resonance imaging for locoregional staging, appropriate liver imaging, selective rather than routine first-line positron emission tomography-computed tomography, and complete colonic visualisation before surgery.[6][7][8][9][4]
• Strengthen pathological quality by identifying and microscopically examining all retrieved lymph nodes, aiming for a laboratory median of at least 12 nodes, and using the modified Ryan tumour regression grading system after neoadjuvant chemoradiation.[10][11][12]
• Deliver appropriate treatment across non-operative management after chemoradiotherapy, management of obstruction, selected local excision, total mesorectal excision, postoperative salvage chemoradiotherapy, and early needs-based palliative care.[13][14][15][16][17][18]
• Centralise rectal cancer surgery in designated cancer centres so that patients have access to appropriate specialist expertise; the wider strategy set a target for 95% of public-hospital cancer surgery to be undertaken in approved centres by 2020.[19][3]
• Promote patient-centred care through clear information, consideration of quality of life and treatment effects, stoma and specialist nursing support, psychological and social support, prehabilitation, and access to voluntary support organisations.[20][17]
• Ensure palliative care is introduced early, assessed continuously and matched to patient need, with the aim of improving quality of life, symptom control, patient satisfaction and caregiver outcomes.[18][21][22]

Implementation

Implement the guideline through multidisciplinary, specialist and centralised care, supported by national clinical-effectiveness governance, National Cancer Control Programme leadership, hospital accountability and structured audit.[1][23][19][24][25]Corporate responsibility rests with each hospital’s Chief Executive Officer, General Manager and Clinical Director, while each multidisciplinary team member is responsible for recommendations relevant to their discipline.[1][20][4]

• Use multidisciplinary team meetings to discuss cancer cases formally and guide diagnostic, treatment and selected imaging decisions, involving professionals experienced in rectal cancer and integrating palliative care specialist services into colorectal cancer meetings.[19][6][26][21]
• Coordinate national implementation through the National Cancer Control Programme, Department of Health, Health Service Executive Acute Hospital Division, Hospital Groups and the Colorectal Cancer National Clinical Leads Group, which supports governance, clinical audit, sharing good practice and problem solving.[3][24][27]
• Develop and implement a local action plan based on the National Clinical Effectiveness Committee implementation guide, specifying actions, lead responsibilities, completion timeframes and expected outcomes.[24]Disseminate guidance through professional networks, colleges, National Cancer Control Programme and National Clinical Effectiveness Committee websites, Health Service Executive communications, training and education.[24][28]
• Build delivery capacity through a rolling capital investment plan for cancer facilities and equipment, annual review of requirements, workforce planning, expanded radiology and sonography training, and coordinated consultant appointments.[29][30][31]Funding for additional implementation resources is to be sought through Health Service Executive service-planning processes.[32][33]
• Apply evidence-based development methods through multidisciplinary steering and development groups, structured clinical questions, systematic searches, validated appraisal tools, health-economic assessment, stakeholder consultation and external expert review.[34][35][36][37]
• Manage conflicts of interest through signed declarations and exclusion from recommendation discussions where conflicts are relevant.[4]Engage patients, advocacy organisations and family representatives in consultation and in considering practical, quality-of-life and values-based aspects of care.[38][35][36]
• Audit guideline implementation and patient outcomes using a five-stage process of planning, standards selection, performance measurement, improvement and sustainability.[25]Monitor centralisation of cancer surgery and the proportion of patients receiving specialist palliative care through National Cancer Strategy key performance indicators, alongside 11 rectal cancer indicators covering referral, staging, treatment timing, multidisciplinary discussion, surgical and pathological quality, radiotherapy and readmission.[39]
• Review performance data, improvement plans, manpower and service planning through regular meetings between the National Cancer Control Programme, cancer-centre senior management and Hospital Group structures.[24]Review the guideline after three years, supported by periodic literature surveillance and National Clinical Effectiveness Committee approval of interim or review-related updates.[36][24]

Monitoring & Evaluation

Implementation is governed through hospital leadership, multidisciplinary teams, the National Cancer Control Programme (NCCP), Hospital Groups and the National Clinical Effectiveness Committee. Corporate responsibility rests with the hospital Chief Executive Officer, General Manager and Clinical Director, while multidisciplinary team members are accountable for recommendations within their professional disciplines.[1][20][24]

• Audit implementation and patient outcomes using a five-stage process of planning, selecting criteria, measuring performance, improving care and sustaining gains.[25]
• Monitor national Cancer Strategy key performance indicators on completion of surgical-service centralisation and the proportion of patients receiving specialist palliative care.[31][22][39]
• Track 11 rectal cancer indicators covering referral to cancer centres, pretreatment rigid sigmoidoscopy, treatment timeliness, multidisciplinary discussion, clinical tumour-node-metastasis staging, abdominoperineal resection, margin documentation and clearance, lymph-node harvest, return to theatre, perioperative radiotherapy and unplanned readmission within 30 days.[39]
• Review performance data, improvement plans, workforce requirements and service planning at regular meetings involving the NCCP, cancer-centre senior management and Hospital Group structures.[24]
• Use the Colorectal Cancer National Clinical Leads Group for clinical audit, professional oversight, sharing good practice and problem solving.[3]
• Monitor pathology performance against a laboratory median of at least 12 lymph nodes retrieved and examined microscopically, with additional retrieval efforts where fewer nodes are identified.[10][11]
• Record tumour regression after preoperative therapy using the four-tier modified Ryan grading system, while recognising that pathological assessment, rather than imaging, is required to identify complete pathological response reliably.[11][12]
• Conduct frequent digital rectal examination, endoscopy and imaging for patients managed non-operatively after chemoradiotherapy, and enrol patients following a watch-and-wait approach on a clinical register.[13]
• Provide serial clinical and radiological surveillance after local excision, particularly during the first three years, and audit outcomes from transanal minimally invasive surgery, transanal endoscopic microsurgery and evolving surgical techniques.[15][16][40]
• Verify equipment and workforce actions through completion of the capital investment plan, annual review, staff training records, confirmation that required staff are in post and completion of workforce assessment.[29][30][41]
• Document departures from recommendations in the patient healthcare record where a recommendation is inappropriate for the individual patient or is declined.[1]
• Manage conflicts of interest through signed declarations and exclusion from recommendation meetings where conflicts are relevant.[4]
• Maintain evidence assurance through documented search strategies, evidence tables, consultation feedback, amendment records, retraction alerts and periodic literature surveillance.[35][36][42][43]
• Review the guideline through the NCCP after three years, subject interim and review updates to National Clinical Effectiveness Committee approval, and publish update information on relevant NCCP and committee websites.[36][24]

The guideline specifies clinical audit, selected performance indicators, verification measures and disease-specific surveillance, but does not provide targets or reporting schedules for every indicator, nor a single comprehensive national implementation evaluation framework.[44][3][5][39]

Costing & Financing

Implementation financing combines quantified diagnostic and operational costs, normal Health Service Executive service-planning processes and a rolling capital investment mechanism. The NCCP commissions and funds guideline development independently of funding-body influence.[4][34][29]

• Provide €695,250 for contrast-enhanced computed tomography of the thorax, abdomen and pelvis, €719,532 for magnetic resonance imaging and €120,450 for computed tomography colonography for the rectal cancer population.[4]
• Seek additional resources through the Health Service Executive service-planning process where recommendations affect resource requirements, while assuming budget-impact calculations cover all patients diagnosed annually who receive public-system treatment.[32][33]
• Fund diagnostic equipment through service planning and an annually reviewed rolling capital investment plan.[29][31]
• Record total operational implementation costs of €511,744 in each of 2020, 2021 and 2022, totalling €1,535,232, excluding revenue costs still to be confirmed following surgical centralisation and workforce planning.[45][20]
• Recognise that pathology, gastroenterology and radiation oncology recommendations are intended to be delivered through current practice and normal service planning without additional healthcare investment.[4]
• Seek potential savings by reducing inappropriate first-line use of positron emission tomography-computed tomography for staging.[4]
• Use budget-impact assessment and economic evidence appraisal when formulating recommendations, including assessment of resource implications and health-system impact.[35][46][37]
• Interpret international economic evidence cautiously because cost-effectiveness thresholds, discount rates, purchasing power, health inflation and analytic perspectives may not transfer directly to Ireland.[37]
• Recognise that Ireland has no explicit cost-effectiveness threshold for non-drug interventions, although approximately €45,000 per quality-adjusted life year is conventionally considered cost-effective.[37]
• Recognise evidence that palliative care is commonly less costly than comparator care, although the cited evidence varies in design and quality.[18]
• Recognise that robot-assisted surgery has higher costs than conventional laparoscopy, while comparative evidence on laparoscopic surgery costs is mixed across settings.[47][48][49]

The document identifies workforce, specialist palliative-care capacity, facilities and capital investment as resource requirements, but does not specify a dedicated financing plan, funding gap or comprehensive allocation by recommendation.[22][27]